HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024
Shots:
- Data from ESLIM-01 study assessing sovleplenib vs PBO in treatment-experienced primary ITP Chinese patients (n=188) in The Lancet Haematology & anticipates a dose-finding study in the US. Data also supported NDA submitted with the NMPA in Jan 2024
- The study showed a sustained durable platelet response with DRR of 48.4% (61/126) vs 0%, ORR of 68.3% & 14.5% (12wks.) vs 70.6% & 16.1% (24wks.) & median time to response of 8 days vs 30 days
- The post-hoc analysis depicted benefits of sovleplenib among ITP patients, irrespective of prior therapies or TPO/TPO-RA treatment, with a DRR of 47.7% vs 0% in patients with ≥4 prior therapies & 46.8% vs 0% in sovleplenib group previously treated with TPO/TPO-RA (74.6%)
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Reports NDA Acceptance with Priority Review by the NMPA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
